Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-25 @ 9:43 PM
Study NCT ID:
NCT05638451
Status:
UNKNOWN
Last Update Posted:
2024-06-05
First Post:
2022-11-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Sponsor:
Zhujiang Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-27
First Submit QC Date:
None
Study First Post Date:
2022-12-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-03
Last Update Post Date:
2024-06-05
Last Update Post Date Type:
ACTUAL